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The newly identified apolipoprotein AV (apoAV) gene
is a key player in determining plasma triglyceride con-
centrations. Because hypertriglyceridemia is a major
independent risk factor in coronary artery disease, the
understanding of the regulation of the expression of this
gene is of considerable importance. We presently char-
acterize the structure, the transcription start site, and
the promoter of the human apoAV gene. Since the per-
oxisome proliferator-activated receptor- (PPAR) and
the farnesoid X-activated receptor (FXR) have been
shown to modulate the expression of genes involved in
triglyceride metabolism, we evaluated the potential role
of these nuclear receptors in the regulation of apoAV
transcription. Bile acids and FXR induced the apoAV
gene promoter activity. 5-Deletion, mutagenesis, and
gel shift analysis identified a heretofore unknown ele-
ment at positions 103/84 consisting of an inverted
repeat of two consensus receptor-binding hexads sepa-
rated by 8 nucleotides (IR8), which was required for the
response to bile acid-activated FXR. The isolated IR8
element conferred FXR responsiveness on a heterolo-
gous promoter. On the other hand, in apoAV-expressing
human hepatic Hep3B cells, transfection of PPAR spe-
cifically enhanced apoAV promoter activity. By dele-
tion, site-directed mutagenesis, and binding analysis, a
PPAR response element located 271 bp upstream of the
transcription start site was identified. Finally, treat-
ment with a specific PPAR activator led to a significant
induction of apoAV mRNA expression in hepatocytes.
The identification of apoAV as a PPAR target gene has
major implications with respect to mechanisms
whereby pharmacological PPAR agonists may exert
their beneficial hypotriglyceridemic actions.
Recent epidemiological studies have shown that hypertri-
glyceridemia is a major independent risk factor for coronary
heart disease, which remains as a major cause of mortality in
the Western world (1–6). Understanding the factors that con-
trol plasma triglyceride levels and the genes that primarily
reflect circulating concentrations of triglyceride-rich lipopro-
teins is thus of major importance and may provide new oppor-
tunities for therapeutic intervention in atherogenic
dyslipidemia.
Pharmacological activation of peroxisome proliferator-acti-
vated receptor- (PPAR1; NR1C1) lowers plasma levels of
triglyceride-rich lipoproteins markedly (7, 8). PPAR is a fatty
acid-activated nuclear transcription factor that regulates the
expression of genes involved in lipid and energy metabolism (9,
10). PPAR heterodimerizes with the retinoid X receptor 
(RXR; NR2B1) and binds to specific DNA sequence elements,
designated PPREs, which consist of a direct repeat of the hexa-
nucleotide core motif PuGGTCA separated by 1 or 2 nucleotides
(DR1 or DR2). PPAR mediates the hypotriglyceridemic effect
of fibrates by regulating the transcription of key genes associ-
ated with different intra- and extracellular metabolic path-
ways. Fibrates increase cellular fatty acid transport and up-
take, conversion to acyl-CoA derivatives, and catabolism by
-oxidation, which results in decreased substrate availability
for triglyceride synthesis and very low density lipoprotein pro-
duction by the liver. In addition, activated PPAR promotes
lipolysis and clearance of triglyceride-rich lipoproteins, thus
decreasing the plasma levels of triglycerides (11). These extra-
cellular effects have been attributed to an increase in LPL
activity via induction of its expression in the liver and reduc-
tion of hepatic expression (and subsequently serum levels) of
apolipoprotein CIII (apoCIII), an established inhibitor of LPL
activity and remnant particle catabolism (7, 12–15).
The farnesoid X-activated receptor (FXR, NR1H4) is another
member of the nuclear receptor superfamily that has been
described as a key regulator in the control of plasma triglycer-
ide levels (16). The expression of FXR is restricted to the liver,
intestine, kidney, and adrenal cortex (17, 18). FXR is a bile
acid-activated receptor that alters transcription by binding as a
heterodimer with RXR to response elements (FXREs) within
the regulatory regions of target genes (16–21). With two excep-
tions, FXREs consist of an inverted repeat of the canonical
hexanucleotide core motif PuGGTCA spaced by one base pair
(IR1) (16). Recently, an inverted repeat with no spacer (IR0) in
the dehydroepiandrosterone sulfotransferase gene (22) and an
everted repeat of the core motif separated by 8 nucleotides
(ER8) in the multidrug resistance-associated protein 2 (MRP2)
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gene (23) have also been reported as elements required for
FXR-dependent transcriptional activation. FXR acts as a bile
acid sensor in the liver, where it mediates the negative feed-
back of bile acid biosynthesis via induction of small het-
erodimer partner (NR0B2) and subsequent repression of cho-
lesterol 7-hydroxylase gene (CYP7A1) expression (24–27), the
rate-limiting enzyme in this pathway, and the sterol 12-hy-
droxylase gene (CYP8B1), the specific enzyme required for
cholic acid synthesis (28). FXR also controls the transport of
bile acids in the liver and intestine. It promotes the excretion of
bile acids from hepatocytes into the bile by induction of bile salt
export pump gene expression (29) and stimulates the entero-
hepatic circulation of bile acids by activation of the transcrip-
tion of ileal-bile acid-binding protein (I-BABP) (30). In addition,
recent findings have shown that FXR regulates lipoprotein
metabolism (16). Phospholipid transfer protein and apoAI, two
major players in plasma high density lipoprotein metabolism,
have been described as FXR target genes (31–33). Studies in
rodents have revealed the role of FXR in regulating triglyceride
levels. The administration of either a synthetic FXR ligand
(GW4064) (34) or a natural FXR ligand (cholic acid) (35) to
rodents resulted in at least a 50% decrease in plasma triglyc-
eride levels. Consistent with these observations, FXR-deficient
mice exhibited a 150% increase in plasma triglyceride levels
(36). Importantly, Edwards and co-workers (35) have reported
that activated FXR induces the expression of apoCII, an obli-
gate cofactor for LPL, which in turn would result in the hydrol-
ysis of triglycerides in chylomicrons and very low density li-
poprotein. These data provide a mechanism to explain the
hypotriglyceridemic effects of the natural FXR activator che-
nodeoxycholic acid (CDCA) when administered to patients with
cholesterol-rich gallstones (37).
Recently, a novel apolipoprotein, designated apoAV, was
suggested to play a significant role on plasma triglyceride
TABLE I
Primers used in this study
Mutated nucleotides are denoted in boldface and lowercase type.
Name Sequence (53 3) Use in this study
JCR 81 hapoAV ex 4 AS GATCCATCGTGTAGGGCTTCAGTTG RLM-RACE
JCR 80 hapoAV ex 4 AS ATGTAGGGCTGGAGGCGAGCCTTCAC RLM-RACE
JCR 79 hapoAV ex 4 AS AGAGGCCTCAGCTTTTCCAGGAACTTG RLM-RACE
JCR 65 hapoAV 2455 F AGTCGGTACCTCAACTGGGCTTGCCCTATGC Transfections
JCR 44 hapoAV 617 C F AGTCGGTACCTCATGGGGCAAATCTCACTTTCGC Transfections
JCR 45 hapoAV 617 T F AGTCGGTACCTCATGGGGCAAATCTTACTTTCGC Transfections
JCR107 hapoAV 535 F AGTCGGTACCCTGCCTGGCTTCCCTTGCTTG Transfections
JCR108 hapoAV 437 F AGTCGGTACCTGTAGTGAAGCTTTCAGG Transfections
JCR109 hapoAV 242 F AGTCGGTACCTGGGTGAGGAGTTCAGCCCCATCC Transfections
JCR110 hapoAV 82 F AGTCGGTACCACGTGGTATTTACTCAGAGC Transfections
JCR 95 hapoAV 18 R AGTCGCTAGCTCACCTGCTCACGTCTGG Transfections
JCR 96 hapoAV 529 R AGTCGCTAGCCTGCTCTGAGAAGACAGG Transfections
JCR 117 hapoAV 617/593 F GATCCTCATGGGGCAAATCTCACTTTCGA EMSA
JCR 118 hapoAV 617/593 R GATCTCGAAAGTGAGATTTGCCCCATGAG EMSA
JCR 141 hapoAV 275/247 F GATCCGGGAAGGTTAAAGGTCATGGGGTTTGGGA EMSA
JCR 142 hapoAV 275/247 R GATCTCCCAAACCCCATGACCTTTAACCTTCCCG EMSA
JCR 155 hapoAV 169/147 F GATCCAGGGCACTCATTAACCCTCTGA EMSA
JCR 156 hapoAV 169/147 R GATCTCAGAGGGTTAATGAGTGCCCTG EMSA
JCR 153 hapoAV 144/117 F GATCCTGCCAGGGAAAGGGCAGGAGGTGAGTGCA EMSA
JCR 154 hapoAV 144/117 R GATCTGCACTCACCTCCTGCCCTTTCCCTGGCAG EMSA
JCR 151 hapoAV 52/31 F GATCCAGAGGCTCAGGGCCCTGGAGA EMSA
JCR 152 hapoAV 52/31 R GATCTCTCCAGGGCCCTGAGCCTCTG EMSA
JCR 157 mitHMGS 113/82 F GATCCTTGTTCTGAGACCTTTGGCCCAGTTTTTCTGA EMSA
JCR 158 mitHMGS 113/82 R GATCTCAGAAAAACTGGGCCAAAGGTCTCAGAACAAG EMSA
JCR 145 hapoAV 484/462 F GATCCGTGGTTGGTCTTTAACCCTATGA EMSA
JCR 146 hapoAV 484/462 R GATCTCATAGGGTTAAAGACCAACCACG EMSA
JCR 123 hapoAV 399/374 F GATCCTGGTAGGTGAACACTGTCCATCTTGA EMSA
JCR 124 hapoAV 399/374 R GATCTCAAGATGGACAGTGTTCACCTACCAG EMSA
JCR 143 hapoAV 298/263 F GATCCGGTGGGCCAGCCAGCAGGTCAGTGGGAAGGTTAAAGA EMSA
JCR 144 hapoAV 298/263 R GATCTCTTTAACCTTCCCACTGACCTGCTGGCTGGCCCACCG EMSA
JCR 165 hapoAV mt DR1 F GATCCGGGAAGGTTAAAcaaCATGGGGTTTGGGA EMSA
JCR 166 hapoAV mt DR1 R GATCTCCCAAACCCCATGttgTTTAACCTTCCCG EMSA
JCR 147 hI-BABP FXRE F GATCCCAGGGTGAATAACCTCGGGGA EMSA
JCR 148 hI-BABP FXRE R GATCTCCCCGAGGTTATTCACCCTGG EMSA
JCR 169 hapoAV dirmut DR1 F GCAGGTCAGTGGGAAGGTTAAAcaaCATGGGGTTTGGGAG Site-directed mutagenesis
JCR 170 hapoAV dirmut DR1 R CTCCCAAACCCCATGttgTTTAACCTTCCCACTGACCTGC Site-directed mutagenesis
JCR 167 hapoAV dirmut IR8 F GCTGGGAGGCAGCTGAGaaCAACTTCTTTcGttCTTCCACGTGG Site-directed mutagenesis
JCR 168 hapoAV dirmut IR8 R CCACGTGGAAGaaCgAAAGAAGTTGttCTCAGCTGCCTCCCAGC Site-directed mutagenesis
JCR 139 hapoAV 109/80 F GATCCAGCTGAGGTCAACTTCTTTTGAACTTCCA Transfections and EMSA
JCR 140 hapoAV 109/80 R GATCTGGAAGTTCAAAAGAAGTTGACCTCAGCTG Transfections and EMSA
JCR 159 hapoAV mt1 IR8 F GATCCAGCTGAGaaCAACTTCTTTTGAACTTCCA Transfections and EMSA
JCR 160 hapoAV mt1 IR8 R GATCTGGAAGTTCAAAAGAAGTTGttCTCAGCTG Transfections and EMSA
JCR 161 hapoAV mt2 IR8 F GATCCAGCTGAGGTCAACTTCTTTcGttCTTCCA Transfections and EMSA
JCR 162 hapoAV mt2 IR8 R GATCTGGAAGaaCgAAAGAAGTTGACCTCAGCTG Transfections and EMSA
JCR 163 hapoAV mt3 IR8 F GATCCAGCTGAGaaCAACTTCTTTcGttCTTCCA Transfections and EMSA
JCR 164 hapoAV mt3 IR8 R GATCTGGAAGaaCgAAAGAAGTTGttCTCAGCTG Transfections and EMSA
JCR36 18 S S GGGAGCCTGAGAAACGGC Real time RT-PCR
JCR37 18 S AS GGGTCGGGAGTGGGTAATTT Real time RT-PCR
XP3 hapoAV S AGCTGGTGGGCTGGAATTT Real time RT-PCR
XP4 hapoAV AS GGCCACCTGCTCCATCAG Real time RT-PCR
BA1 hBSEP S GGTGAGAAAAGAGAGGTTGAAAGG Real time RT-PCR
BA2 hBSEP AS CCACACGAATCCAGTAAAGAATCC Real time RT-PCR
BA3 hSHP S CGCCCTATCATTGGAGATGT Real time RT-PCR
BA4 hSHP AS AGGAGCATTGGGTCACCTC Real time RT-PCR
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metabolism. Pennacchio et al. (38) described the discovery of
apoAV when 200 kb of orthologous sequences spanning the
apoAI/CIII/AIV gene cluster were compared in humans and
mice. At the same time, van der Vliet et al. (39) identified
apoAV as a protein associated with an early phase of liver
regeneration. Interestingly, the predicted amino acid sequence
showed appreciable homology with apoAI and apoAIV. Evi-
dence for the involvement of apoAV in triglyceride metabolism
was obtained in mice, in which serum triglyceride concentra-
tions were decreased to one-third when a human apoAV trans-
gene was overexpressed (38) or adenoviral vectors expressing
mouse apoAV were injected (40). Conversely, plasma triglycer-
ide levels were 4-fold elevated in knockout mice lacking apoAV
compared with their wild-type littermates (38). Furthermore,
single nucleotide polymorphisms (SNPs) across the locus of the
apoAV gene were found to be significantly associated with
FIG. 1. Characterization of the structure, the transcription start site, and the promoter of the human apoAV gene. A, schematic
representation of the exon-intron structure of the human apoAV gene. Exons are shown in boxes with translated regions shaded in black. The
predicted initiation codon ATG is located in the second exon. The relative positions of the gene-specific primers used in the RLM-RACE are
indicated by horizontal arrows. The last exon has two alternative polyadenylation sites (39), and the second exon has two alternative acceptor sites.
A bent arrow depicts the transcription start site. The relative position of an SNP (A3G) is shown. B, the structure of the human apoAV gene is
compared with that of the other components of the human apolipoprotein gene cluster. The structures of human apoAI and apoCIII genes are
deduced from sequences in NM_000039, NM_000040, X01038, X03120, and J00098. The structure of the apoAIV gene is taken from Ref. 50. The
exon lengths in nt are indicated by numbers above the bars. Numbers below the lines depict intron lengths. C, nucleotide sequence corresponding
to the 5 region of the human apoAV gene. Exons are in boldface. Intron sequences are shown in lowercase. The predicted initiation codon is double
underlined. Numbers are relative to the transcription start site (1). A putative TATA box and the DR1 and IR8 elements described in the current
study are boxed. The consensus receptor-binding hexads are indicated by horizontal arrows.
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plasma triglyceride and very low density lipoprotein mass lev-
els in several ethnic groups (38, 41–45). Notwithstanding, the
specific biological functions of apoAV in triglyceride metabo-
lism or liver regeneration are still unknown. Pennacchio et al.
(38) reported a genomic organization of human apoAV with
four exons. In contrast, van der Vliet et al. (39) reported three
exons. Both groups showed that the expression of apoAV
mRNA was restricted to the liver.
The current studies were undertaken to provide a compre-
hensive analysis of the regulation of human apoAV gene ex-
pression. We presently describe the genomic structure, the
transcription start site, and the promoter of the human apoAV
gene. Inasmuch as PPAR and FXR play key roles in the
regulation of genes involved in triglyceride metabolism, we
sought to evaluate their potential effects on human apoAV gene
expression. We show that a novel FXRE is present in the
promoter of human apoAV and demonstrate that human
apoAV is a bona fide PPAR target gene. Our findings provide
new insights into the mechanisms whereby PPAR and its
ligands lower plasma triglyceride levels.
EXPERIMENTAL PROCEDURES
RNA Ligase-mediated Rapid Amplification of cDNA Ends (RLM-
RACE)—The start of transcription of human apoAV was identified by
using GeneRacerTM (Invitrogen). This kit provides a modification of
the RACE method that ensures the capture of only full-length 5 ends
of specific transcripts via elimination of truncated messages from the
amplification process. Human liver total RNA (Clontech) was treated
with calf intestinal phosphatase and tobacco acid pyrophosphatase
according to the instructions of the kit. After the selective ligation of
an RNA oligonucleotide to the 5-ends of decapped mRNA, first strand
cDNA synthesis was carried out with the ThermoScriptTM RNase H
reverse transcriptase (Invitrogen; not supplied in the GeneRacerTM
kit) at 50 °C for 50 min and a reverse human apoAV-specific primer
(JCR81; see Table I). The cDNA 5-end was amplified by using Plati-
numTM TaqDNA Polymerase High Fidelity (Invitrogen; not supplied
in the GeneRacerTM kit) and primers GeneRacerTM 5 and JCR80
(Table I). The PCR conditions were as follows: 94 °C for 2 min fol-
lowed by 30 cycles of 94 °C for 30 s, 65 °C for 30 s, and 68 °C for 1 min.
The sample was then diluted 20-fold, and 1 l was used in a second
PCR with nested primers (GeneRacerTM 5 Nested and JCR79). DNA
products were cloned into pCR4-TOPOTM vector (Invitrogen) and
then sequenced.
Plasmids—Several constructs containing the 5-flanking region of
human apoAV (2455/18, 617/18, 617/529, 535/18, 437/
18, 242/18, and 82/18, relative to the transcription start site
reported in this paper) were obtained by PCR from human bacterial
artificial chromosome-RPCI-11–442E11 DNA (BACPAC Resources,
Children’s Hospital Oakland Research Institute) with PlatinumTM
TaqDNA Polymerase High Fidelity (Invitrogen). Forward primers were
tailed with a KpnI restriction site. Reverse primers were tailed with an
NheI site. The PCR products were digested with KpnI and NheI
and cloned into the corresponding sites of the promoterless firefly
(Photinus pyralis) luciferase reporter plasmid pGL3-basic (Promega),
generating p2455/18hAvLUC, p617/18hAvLUC, p617/
529hAvLUC, p535/18hAvLUC, p437/18hAvLUC, p242/
18hAvLUC, and p82/18hAvLUC. Site-directed mutagenesis of the
constructs p2455/18hAvLUC, p617/18hAvLUC, and p242/
18hAvLUC were accomplished using the QuikChangeTM site-directed
mutagenesis kit (Stratagene) according to the recommendations of the
manufacturer. The vector pGL3-TK contains a fragment corresponding
to nt109 to20 of the thymidine kinase (TK) gene promoter of herpes
simplex virus (46) subcloned into the BglII/HindIII sites of the pGL3-
basic vector. The reporter plasmids p(AvIR8)n-TK (n  1–4) were gen-
erated by insertion of 1–4 copies of a double-stranded oligonucleotide
(obtained by annealing JCR139 and JCR140; see Table I) containing the
sequences spanning nt 109 to 80 into the BglII site of pGL3-TK.
Similarly, the four-copy mutant IR8 constructs p(mt1AvIR8)4-TK,
p(mt2AvIR8)4-TK, and p(mt3AvIR8)4-TK were generated by annealing
oligonucleotides JCR159 with JCR160, JCR161 with JCR162, and
JCR163 with JCR164, respectively, before ligation into BglII-digested
pGL3-TK. The luciferase reporter plasmid p(ER8)4-TK contains four
copies of the rat MRP2 ER8 element (23) in front of TK promoter and
was provided by L. Moore (GlaxoSmithKline, Research Triangle Park,
NC). Plasmids expressing human cDNAs for PPAR, RXR, and FXR
were provided by J. A. Holt and J. M. Maglich (GlaxoSmithKline,
Research Triangle Park, NC). The backbone of those plasmids was the
mammalian expression vector pSG5 with a modified polylinker. Plas-
mid DNA was prepared using the Qiagen endotoxin-free maxiprepara-
tion method and quantitated spectrophotometrically. The integrities of
all plasmids were verified by DNA sequencing.
Cell Transfection and Reporter Assays—Human hepatoblastoma
Hep3B and monkey kidney CV-1 cell lines were cultured in Eagle’s
basal medium supplemented with nonessential amino acids, 2 mM
L-glutamine, 100 units/ml penicillin, and 100 g/ml streptomycin sul-
fate (medium A) and 10% (v/v) fetal calf serum (FCS). On day 0, cells
were seeded on 24-well plates at a density of 3  105 or 5  104
cells/well for Hep3B or CV-1, respectively. On day 1, cells were trans-
fected with FuGENE 6 reagent (Roche Applied Science) according to the
manufacturer’s instructions. Typically, each well of a 24-well plate
received 100 ng of firefly luciferase reporter plasmid and, when indi-
cated, 200 ng of plasmids expressing human PPAR or FXR. Effector
plasmid dosage was kept constant by the addition of appropriate
amounts of the empty expression vector pSG5. 100 ng/well of a sea
pansy (Renilla reniformis) luciferase plasmid pRL-TK (Promega) was
included in all transfections as an internal control for transfection
efficiency. After 5 h, cells were switched to medium A supplemented
with 10% delipidated calf serum (Sigma) in the presence, when indi-
cated, of either 1 M GW9003 (GlaxoSmithKline), 50 or 100 M CDCA,
1 M GW4064 (GlaxoSmithKline), or the vehicle (Me2SO). On day 3, cell
lysates were prepared by shaking the cells in 200 l of 1 Promega lysis
buffer for 15 min at room temperature. Firefly and Renilla luciferase
activities were measured using a Dual-Luciferase Reporter Assay
System (Promega) and a Lumistar luminometer (BMG Lab Technolo-
gies). Firefly luciferase activity values were divided by Renilla lucifer-
ase activity values to obtain normalized luciferase activities. To facilitate
comparisons within a given experiment, activity data were presented
either as relative luciferase activities or as -fold induction over the nor-
malized activity of the reporter plasmid in the absence of nuclear receptor
cotransfection and agonist supplementation. All transfection experiments
were performed at least three times and with each experimental point
done in triplicate. The data are expressed as the means  S.D. Statistic
significance analysis were done with Student’s t test.
Treatment of HepG2 Cells—On day 0, human hepatoblastoma
HepG2 cells were plated on 24-well plates at 3.5  105 cells/well in
medium A supplemented with 10% (v/v) FCS. On day 1, the medium
was replaced with fresh medium A supplemented with 1% (v/v) FCS
and 1 M GW9003, 1 M GW4064, or vehicle (Me2SO). On day 3, the
FIG. 2. Transactivation of the human apoAV gene promoter by
PPAR. Hep3B cells were transfected with a plasmid containing a
luciferase reporter gene driven by the 5-flanking region (617/18) of
the human apoAV gene or the empty pGL3-basic vector along with a
plasmid expressing human PPAR or the empty vector pSG5 as control.
Cells were treated with vehicle alone or 1 M GW9003 for 48 h, and
luciferase activities were measured and expressed as described under
“Experimental Procedures.” *, p  0.001 versus control.
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cells were washed twice with phosphate-buffered saline and harvested
for isolation of RNA.
Treatment of Primary Cultured Cynomolgus Monkey Hepatocytes—
Cynomolgus monkey hepatocytes (batch L-1811; Biopredict) were
seeded on day 0 at a density of 6  105 cells/well on 12-well plates in
Williams’ medium E supplemented with 2 mM L-glutamine, 100
units/ml penicillin, 100 g/ml streptomycin sulfate, 4 g/ml insulin
(medium B), and 10% (v/v) FCS. On day 1, cells were switched to
medium B containing 100 nM dexamethasone, 1% (v/v) FCS and 1 M
GW9003, 1 M GW4064, 30 M lithocholic acid (LCA), or vehicle (Me2SO).
After 24 h, a fresh experimental medium was provided. On day 3, the cells
were washed twice with PBS and harvested for isolation of RNA.
FIG. 3. Localization of a PPAR response region in the human apoAV promoter by progressive deletion analysis. Hep3B cells were
cotransfected with reporter plasmids containing the firefly luciferase gene driven by progressively 5-shortened fragments of the apoAV promoter
as indicated together with the empty vector pSG5 or a plasmid expressing human PPAR. Cells were treated with vehicle or 1 M GW9003 for 48 h,
and luciferase activities were measured as described under “Experimental Procedures.” Results are expressed as -fold induction over control. LUC,
luciferase.
FIG. 4. Functional effects of mutations in the DR1 element on the response of the human apoAV promoter to PPAR. A, human
apoAV gene promoter sequence surrounding the DR1 element. The gray box denotes the DR1 sequence. The AGGTCA half-sites are indicated by
horizontal arrows. The wild-type nucleotides that were modified by site-directed mutagenesis are underlined. The corresponding 263G3C/
262G3A/261T3A mutated nucleotides are shown below the vertical arrow and within the gray square. B, Hep3B cells were transfected with
a plasmid expressing human PPAR or the empty pSG5 vector as control together with reporter constructs containing the wild-type or site-directed
mutated 5-flanking regions (617/18) of the human apoAV gene or the empty pGL3-basic vector as negative control. Cells were treated with
vehicle or GW9003 (1 M) for 48 h, and luciferase activities were measured and expressed as described under “Experimental Procedures.” *, p 
0.05 versus control. NS, not significant. The cross depicts the presence of site-directed mutations in the DR1 element. LUC, luciferase.
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Real Time PCR Quantification of mRNAs—Total RNA was prepared
from primary cynomolgus hepatocytes, human THP-1 monocytes differ-
entiated to macrophages, HepG2, Hep3B, Huh-7, and Caco-2 cells with
the RNeasyTM Mini kit, the QIAshredderTM homogenizers, and the
RNase-Free DNase set (Qiagen) according to the manufacturer’s in-
structions. A 1-g aliquot was used as a template for cDNA synthesis,
employing the TaqManTM Reverse Transcription Reagents kit (Applied
Biosystems). Specific primers for each gene were designed with Primer
Express Software (PerkinElmer Life Sciences). The sequences of for-
ward and reverse primers are shown in Table I. The specificity of the
primers was verified by showing that the real time reverse tran-
scriptase (RT)-PCR reaction product generated a single band after
agarose gel electrophoresis. In addition, each couple of primers was
tested in successive dilutions of cDNA to analyze and validate its
efficiency. The reactions contained, in a final volume of 25 l, 5 l of
diluted (1:10) cDNA, a 300 nM concentration of the forward and reverse
primers, and 2 SYBRTM Green PCR Master Mix (Applied Biosystems).
Real time PCRs were carried out in 96-well plates by using the ABI
PRISMTM 7700 sequence detection system (Applied Biosystems). Since
there is a high level of sequence identity for apoAV between humans
and monkeys, the primers were valid for RNA from both primates.
Levels of apoAV were normalized to 18 S to compensate for variations
in input RNA amounts (18 S levels were unaffected by the treatments).
All points were performed in triplicate during two independent exper-
iments, and the RT-PCRs were carried out in duplicate for each sample.
The relative amounts of mRNAs were calculated using the Comparative
CT method as described in Ref. 55.
In Vitro Transcription/Translation and Electrophoretic Mobility
Shift Assay (EMSA)—Human PPAR, RXR, and FXR proteins were
synthesized in vitro from the corresponding expression plasmids in
rabbit reticulocyte lysate by using the TNT® Quick Coupled transcrip-
tion/translation system (Promega) according to the instructions of the
manufacturer. In order to obtain an unprogrammed lysate as a negative
control for EMSA, a reaction was performed with the empty vector
pSG5. Double-stranded oligonucleotides were radiolabeled by fill in
with the Klenow fragment of DNA polymerase I and used as probes. For
competition experiments, increasing -fold molar excesses of unlabeled
probes were included during a 15-min preincubation on ice. Protein-
DNA binding assays were performed as described (47). AvDR1 is a
double-stranded oligonucleotide corresponding to nt 275 to 247 of
human apoAV promoter. mtAvDR1 is a modified version of AvDR1 that
contains mutations corresponding to nt 263(G3C)/262(G3A)/
261(T3A). The control probe used in EMSA with PPAR-RXR con-
tains the PPRE of the rat mitochondrial 3-hydroxy-3-methylglutaryl-
CoA synthase (mitHMGS) gene promoter (48). The probe AvIR8
contains the sequence spanning nt 109 to 80 of the human apoAV
promoter. The mutations present in the modified versions of AvIR8
(mt1AvIR8, mt2AvIR8, and mt3AvIR8) are shown in Fig. 10B. The
probe used as a control for competition experiments with FXR-RXR
contains the FXRE of the human I-BABP gene promoter (30). Samples
were electrophoresed at 4 °C on a 4.5% polyacrylamide gel in 0.5 TBE
buffer (45 mM Tris, 45 mM boric acid, 1 mM EDTA, pH 8.0). Gels were
dried and analyzed using an Amersham Biosciences PhosphorImager
STORM 860 and ImageQuant software (Amersham Biosciences).
RESULTS
Characterization of the Structure of the Human ApoAV Gene,
Identification of an Alternatively 5-Untranslated Region, and
Determination of the Transcription Start Site—Two previous
reports coincided to show by Northern blot analysis that apoAV
has transcripts of 1.3 and 1.9 kb in the human liver, which
are likely to result from alternative polyadenylation (38, 39).
However, the number of exons and the details of the exon/
intron organization in the 5 region of the human apoAV gene
FIG. 5. PPAR-RXR heterodimers can specifically bind to the DR1 element of the human apoAV promoter. A, EMSAs were
performed using in vitro transcribed/translated human PPAR (2.5 l), human RXR (2.5 l), or unprogrammed reticulocyte lysate (), when
indicated, and labeled double-stranded oligonucleotides corresponding to the indicated fragments of the human apoAV gene promoter as described
under “Experimental Procedures.” The lysate volumes were kept constant by the addition of unprogrammed lysate. CONTROL, a labeled probe
that contains the PPRE of the mitHMGS gene (3-fold less was used). B, competition experiments for binding of PPAR-RXR heterodimers to the
labeled double-stranded oligonucleotides corresponding to nt275 to247 (AvDR1) were performed by adding a 10-, 50-, and 250-fold molar excess
of the indicated unlabeled probes. mtAvDR1 is a modified version of wtAvDR1 with mutations corresponding to nt 263G3C/262G3A/
261T3A. The specific PPAR-RXR-PPRE complex is indicated by an arrow. CONT, PPRE of mitHMGS gene (48); wt, wild type; mt, mutated.
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have been contradictory. In order to delineate the structure of
the gene, we performed RLM-RACE. This powerful technique
is a modification of the RACE method that ensures the capture
of only full-length specific transcripts via elimination of trun-
cated messages from the amplification process. Thus, using
antisense primers from the 3 region of mRNA, it is possible to
amplify all of the upstream exons and hence to detect the
presence of alternatively spliced exons. A primer was designed
at the last exon of human apoAV, and a specific reverse tran-
scription was carried out from human liver RNA. In order to
avoid secondary structures of mRNA, we made the first strand
cDNA synthesis at 50 °C with a reverse transcriptase having a
high thermal stability (see “Experimental Procedures”). Subse-
quently, specific PCRs were performed using additional apoAV
nested primers (Table I). The PCR products were cloned and
sequenced. Based on the genomic sequence spanning part of
human chromosome 11q23 present in the GenBankTM data
bank (accession number AC007707), we obtained an exon/in-
tron organization of apoAV with two distinct 5-untranslated
regions (Fig. 1A). As shown in Fig. 1B, the four-exon structure
of apoAV is also present in apoAI and apoCIII genes (as de-
duced from the analysis of sequences in NM_000039,
NM_000040, X01038, X03120, and J00098) but not in apoAIV
(structure taken from Ref. 50). The most important feature of
the RLM-RACE method is that it permits the determination of
the transcription start site with more precision than the primer
extension and the classic 5-RACE procedures. As shown in
Fig. 1C, a single human apoAV transcription start site was
identified. The newly identified first exon, which was named
exon 1, has only 12 untranslated nt and contains a stop codon
in frame with the first ATG, which is located in the following
exon (Fig. 1C). Interestingly, a sequence of 24 nt was observed
just after exon 1 in 4 of 20 clones. This novel sequence, which
we named exon 2a, was flanked on the 5 side by an ag con-
sensus splice acceptor site on the first intron and on the 3 side
by the exon previously described in the literature as exon 1,
which we renamed exon 2b (Fig. 1C). Therefore, the second
exon has either 57 nt (exon 2b) or 81 nt (exon 2a plus exon 2b),
depending on the utilization of an internal acceptor site (Fig.
1A). No novel exons were observed, so the coding region is
distributed in three exons, in agreement with earlier results
(39). Considered together, the human apoAV gene consists of
four exons, the second exon with two alternative acceptor sites
and the last exon with two alternative polyadenylation sites.
On the other hand, we noticed the presence of an SNP (A3G)
3 nt upstream from the predicted translation start codon
(Fig. 1C).
Expression of ApoAV in Human Cell Lines—Previously pub-
lished Northern blots with RNA from several different human
tissues have shown that apoAV expression is restricted to the
liver (38, 39). We carried out real time PCR quantification
assays with RNA from several human cell lines with different
origins. We found that apoAV is expressed in HepG2 and
Hep3B hepatoma cells with levels comparable with the liver,
but not in hepatic Huh-7 cells. Consistent with the hepatic
specific expression, intestinal Caco-2 cells and THP-1 mono-
cytes differentiated to macrophages showed no detectable ex-
pression of apoAV (data not shown).
Cloning and Characterization of the Human ApoAV Gene
Promoter—Analysis of the 5-flanking region of the human
apoAV gene identified a TATA box 30 nt upstream of position
1 (Fig. 1C), further confirming the mapped transcription
start site. No consensus Sp1 binding sites were found within
the first 3 kb, although several putative nuclear receptor re-
sponse elements containing imperfect repeats of the half-site
PuGGTCA were detected (see below). To investigate whether
this 5-flanking region could drive transcription of a reporter
gene, we subcloned 0.6 kb of the human apoAV sequence
upstream of the transcription start site into the firefly lucifer-
ase pGL3-basic vector. The resulting construct, p617/
18hAvLUC, was transiently transfected into HepG2 and
Hep3B cells. The activity of this construct was about 5-fold the
activity of the parental promoterless vector in both cell lines
(Fig. 2). Next, we observed that neither the addition of a more
upstream region, in construct p2455/18hAvLUC, nor the
inclusion of the first intron, in p617/529hAvLUC, substan-
tially altered promoter activity (data not shown).
Overexpression of the Nuclear Receptor PPAR Enhances the
Activity of the Human ApoAV Gene Promoter—ApoAV is an im-
portant determinant of plasma triglyceride levels (38, 40–45).
Inasmuch as PPAR regulates the expression of genes involved
in triglyceride metabolism (10), we evaluated whether this nu-
FIG. 6. PPAR agonists enhance apoAV mRNA levels in human HepG2 cells and primary cynomolgus hepatocytes. Hepatocytes
isolated from cynomolgus liver (Cyno) and human hepatoma HepG2 cells were treated for 48h with vehicle (Control) or 1 M GW9003. Total RNA
was extracted for analysis by real time RT-PCR as described under “Experimental Procedures.” Specific apoAV mRNA levels normalized to 18 S
content are expressed relative to untreated cells set as 100 (mean  S.D.). *, p  0.01 versus control.
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clear receptor modulates human apoAV gene expression. For this
purpose, transient transfection studies were performed in Hep3B
cells. Cotransfection of a human PPAR expression plasmid re-
sulted in a significant increase of the activity of the firefly lucif-
erase reporter gene driven by the 617/18 sequence of the
human apoAV promoter (Fig. 2). The effect of PPAR overexpres-
sion was promoter-dependent, because it was not observed with
the promoterless pGL3-basic vector. In line with previous studies
in hepatic cells (48, 49), transiently transfected PPAR showed
substantial constitutive activity, possibly due to activation by
endogenous ligands. Nevertheless, we observed that it could be
further activated upon the exogenous addition of the specific
PPAR ligand GW9003 (Fig. 2).
Mapping of the Human ApoAV Promoter Site Conferring
Responsiveness to PPAR—In order to localize the region re-
quired for PPAR activation, a series of progressively larger
5-deletion human apoAV promoter constructs from nt 2455
to 18 were transiently transfected into Hep3B cells together
with a human PPAR expression plasmid in the presence or
absence of GW9003. As shown in Fig. 3, the sequence upstream
to position 437 can be deleted without loss of the response to
PPAR. However, further deletion up to nt 242 eliminated
the PPAR responsiveness. Analysis of the sequence in the
437/242 fragment revealed two potential hexamer binding
sites separated by a single nucleotide between nt 271 and
259 (Fig. 1C), thereby conforming to the DR1 response ele-
ment for PPAR (PPRE).
To unequivocally characterize the DR1 as a PPRE, Hep3B
cells were cotransfected with a human PPAR expression vec-
tor and an apoAV promoter-luciferase reporter plasmid in
which the DR1 sequence was mutated in the 3-hexamer (Fig.
4A). In contrast to the native promoter construct, PPAR and
GW9003 had only a modest residual effect on the luciferase
gene expression of the construct bearing the mutated DR1 (Fig.
4B). These results demonstrate that this DR1 indeed confers
PPAR response to the apoAV promoter.
Binding Analysis of PPAR-RXR Heterodimers to the
apoAV DR1 Element—PPAR binds to DNA as a heterodimer
with RXR (10). To investigate whether PPAR-RXR het-
erodimers directly bind to the human apoAV gene promoter,
radiolabeled double-stranded oligonucleotides corresponding to
portions of the 617/18 fragment of the apoAV promoter
were used as probes in EMSA experiments (Fig. 5). As ex-
pected, the addition of in vitro translated PPAR and RXR
proteins resulted in the appearance of a robust retarded com-
plex when using a 275/247 fragment containing the apoAV
DR1 (Fig. 5A, lane 4), but not when 617/593, 169/147,
144/117, and52/31 probes (Fig. 5A, lanes 2, 6, 8, and 10,
respectively) or 484/462, 399/374, 298/263, and
109/80 fragments were employed (data not shown). Fur-
thermore, the specificity of the RXR-PPAR heterodimer-
apoAV DR1 interaction was demonstrated by competition anal-
ysis. The formation of the retarded complex was inhibited by
the addition of increasing concentrations of either the unla-
beled apoAV DR1 probe (Fig. 5B, lanes 5–7) or a cold probe
containing the PPRE of the mitHMGS gene (Fig. 5B, lanes
11–13). In contrast, a cold double-stranded oligonucleotide that
is equivalent to the apoAV DR1 probe but harbors point muta-
tions in the 3 half-site (nt 263G3C/262G3A/261T3A
in Fig. 4A) could not displace the labeled wild-type element
(Fig. 5B, lanes 8–10). In addition, it is worth noting that a more
retarded band of the labeled apoAV DR1 containing probe was
visible upon the addition of RXR alone (Fig. 5B). Further
investigations will be done to elucidate the nature of this band.
Taken together, these results show that this apoAV DR1 is a
genuine PPRE.
FIG. 7. Bile acids induce human apoAV promoter activity via
FXR. Hep3B (A and C) and CV-1 (B) cells were transfected with a
plasmid containing a luciferase reporter gene driven by the 5-flanking
region (617/18) of the human apoAV gene or the empty pGL3-basic
vector along with a plasmid expressing human FXR or the empty vector
pSG5 as control. Cells were treated for 48 h with vehicle alone, with
increasing concentrations of CDCA (A and B), or with 1 M GW4064 (C),
and luciferase activities were measured and expressed as described
under “Experimental Procedures.” Significant differences compared
with the corresponding pSG5 control are as follows: *, p 0.005; **, p
0.001; #, p  0.0005.
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PPAR Agonists Induce ApoAV mRNA Levels in Human
Hepatoma HepG2 Cells and Primary Cultures of Cynomolgus
Hepatocytes—To analyze whether apoAV mRNA expression is
regulated by PPAR agonists, primary hepatocytes isolated
from cynomolgus liver and human hepatoma HepG2 cells were
incubated for 48 h in medium containing GW9003 or vehicle.
As determined by quantitative real time RT-PCR, treatment
with the PPAR agonist markedly increased apoAV mRNA
levels (Fig. 6).
Bile Acids Induce Human apoAV Gene Promoter Activity via
the Nuclear Receptor FXR—FXR regulates lipoprotein metab-
olism (16), and FXR agonists have hypotriglyceridemic effects
on rodents and humans (34, 35, 37). To determine whether FXR
and bile acids are able to modulate the apoAV gene promoter
activity, transient transfection assays were performed with a
firefly luciferase reporter gene expression vector driven by the
617/18 sequence of the human apoAV promoter. In Hep3B,
the bile acid CDCA alone induced apoAV promoter activity to
some extent (Fig. 7A). Cotransfection of a human FXR expres-
sion plasmid significantly enhanced CDCA-induced promoter
activity. To further confirm the role of FXR in the bile acid-
induction of the apoAV promoter, monkey kidney CV-1 cells, a
cellular model frequently used in order to avoid the background
of endogenous FXR (19–21, 32), were also employed. As shown
in Fig. 7B, promoter activity was unaffected by CDCA in the
absence of FXR supplied exogenously. By contrast, cotransfec-
tion of FXR led to a more than 10-fold induction of apoAV
promoter activity in the presence of 100 M CDCA. In both cell
lines, the transactivation of the apoAV promoter-luciferase re-
porter plasmid by CDCA via FXR was dose-dependent (Fig. 7,
A and B). Moreover, the effects of CDCA and FXR were promoter-
dependent, because they were not observed with the promoter-
less pGL3-basic vector. Since bile acids may also exert their
actions through FXR-independent pathways, we also tested the
synthetic nonsteroidal specific FXR ligand GW4064 (34). As
expected, treatment of Hep3B cells with GW4064 further en-
hanced the transactivation of the apoAV promoter by FXR (Fig.
7C). These data clearly demonstrated the existence of an FXR
response element in the promoter of the human apoAV gene.
A Novel Element in the Human ApoAV Promoter Is Required
for Transcriptional Activation by FXR—To localize the region
within the human apoAV promoter that confers transcriptional
responsiveness to FXR and bile acids, a series of constructs
containing sequential 5-deletions from nt 2455 to 18 of
the apoAV promoter in front of the firefly luciferase reporter
gene were transiently transfected into CV-1 cells together
with a human FXR expression plasmid in the presence or the
absence of 100 M CDCA (Fig. 8). The results showed that the
nucleotide sequence between 2455 and 242 could be re-
moved without preventing strong activation of the reporter
gene by bile acid-activated FXR. In contrast, deletion of the
fragment between nt 242 and 82 completely abolished the
induction of apoAV promoter activity by CDCA-activated
FXR, indicating that this region mediates the effects of bile
acids.
Surprisingly, analysis of the sequence in the 242/82 frag-
ment did not reveal any of the previously described FXR re-
sponse element (IR0, IR1, or ER8) motifs (16, 22, 23). The only
repeat of the hexanucleotide core motif PuGGTCA with a low
degree of degeneration present within this region corresponds
to an inverted repeat separated by 8 nucleotides (IR8) between
nt 103 and 84 (Fig. 1C). Although a response element with
this kind of organization has never been reported before, we
mutated both halves of the IR8 site (Fig. 9A) in the context of
the apoAV promoter on both the longest plasmid (Fig. 9B) and
the shortest construct that still responds to FXR (Fig. 9C) and
performed transient transfections in Hep3B cells. Whereas co-
transfection of an FXR expression plasmid significantly en-
hanced wild-type apoAV promoter activity, FXR failed to in-
duce the activity of the mutated constructs. These results
unequivocally show that this IR8 element is required for the
response to FXR and that there is no other FXRE in the
promoter of human apoAV.
The ApoAV IR8 Element Confers FXR Responsiveness to Het-
erologous Promoters—To evaluate whether this IR8 element
could confer FXR responsiveness to a heterologous promoter,
we linked the apoAV IR8 site upstream of the TK promoter and
the luciferase reporter gene. Reporter constructs containing
FIG. 8. The region between nt242 and82 of the human apoAV promoter mediates the response to bile acid-activated FXR. CV-1
cells were cotransfected with reporter plasmids containing the firefly luciferase gene driven by progressively 5-shortened fragments of the apoAV
promoter together with the empty vector pSG5 or a plasmid expressing human FXR. Cells were treated with vehicle or 100 M CDCA for 48 h, and
luciferase activities were measured as described under “Experimental Procedures.” Results are expressed as -fold induction over control. LUC,
luciferase.
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1–4 copies of the apoAV IR8 element were transiently trans-
fected into Hep3B cells along with a human FXR expression
plasmid in the presence or the absence of CDCA. As demon-
strated in Fig. 10A, bile acid-activated FXR enhanced the ac-
tivity of apoAV IR8-driven promoter constructs, whereas the
reporter construct with the TK promoter alone was not stimu-
lated at all. Indeed, an induction of about 50-fold was reached
with four copies, and the response was manifested in a copy
number-dependent manner, thereby confirming that the IR8
element functions as an FXRE.
Next, the effects of selective mutations of each half-site in the
IR8 element (Fig. 10B) were examined in Hep3B cells trans-
fected with reporter constructs driven by four copies of the
apoAV IR8 in front of the TK promoter. The FXR-dependent
induction was abrogated when mutations were introduced in
any half-site (Fig. 10C). These observations confirm the orga-
nization of this FXR response element as an inverted repeat of
the canonical hexanucleotide separated by 8 nt. Finally, the
ability of the apoAV IR8 to respond to FXR and bile acids was
assessed by comparison with the ER8 element described in the
promoter of MRP2 gene (23). The FXR-dependent response of
the MRP2 ER8 in front of TK was 2.5-fold higher than the
apoAV IR8 (Fig. 10A).
FIG. 9. Mutation of the IR8 element on the human apoAV pro-
moter eliminates the response to FXR. A, human apoAV gene
promoter sequence surrounding the IR8 element. The gray box denotes
the IR8 sequence. The AGGTCA half-sites are indicated by horizontal
arrows. The wild-type nucleotides that were modified by site-directed
mutagenesis are underlined. The corresponding mutated nucleotides
are shown below the vertical arrows and within the gray squares. B and
C, Hep3B cells were transfected with a plasmid expressing human FXR
or the empty pSG5 vector as control together with reporter constructs
containing the wild-type or site-directed mutated 5-flanking regions of
the human apoAV gene or the empty pGL3-basic vector as negative
control. Cells were treated for 48 h with vehicle, 100 M CDCA, or 1 M
GW4064, and luciferase activities were measured and expressed as
described under “Experimental Procedures.” Significant differences
compared with the corresponding pSG5 control are as follows: *, p 
0.001; **, p  0.0005. The crosses depict the presence of site-directed
mutations in the IR8 element. LUC, luciferase.
FIG. 10. The IR8 element present in the promoter of the human
apoAV gene (AvIR8) confers FXR responsiveness to heterolo-
gous promoters. A, the apoAV IR8 element confers transactivation by
bile acid-activated FXR in a copy number-dependent manner. Hep3B
cells were transiently transfected with plasmids expressing human
FXR or the empty pSG5 vector as control, together with reporter con-
structs containing 1–4 copies of the sequence corresponding to nt 109
to 80 (AvIR8) of the human apoAV gene promoter or four copies of the
ER8 element present in the MRP2 gene promoter (ER8) cloned in front
of a heterologous TK promoter-driven luciferase. The empty pGL3-TK
reporter vector was used as negative control. Cells were treated with
vehicle or 100 M CDCA for 48 h, and luciferase activities were meas-
ured as described under “Experimental Procedures.” Results are ex-
pressed as -fold induction over control. B, human apoAV gene promoter
sequence surrounding the IR8 element and mutated versions used in C.
The hexameric consensus sites are in boldface type, and their orienta-
tions are indicated by arrows. Mutations in half-sites are shown in
lowercase type and within gray squares. C, functional effects of muta-
tions on hexameric consensus sites. Experiments were performed as in
A with reporter constructs containing four copies of the wild-type (wt)
(wtAvIR8) or mutant (mt1AvIR8, mt2AvIR8, mt3AvIR8) sequences cor-
responding to nt 109 to 80 of the human apoAV gene promoter
cloned in front of TK promoter-driven luciferase.
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The FXR-RXR Heterodimer Binds Specifically to the ApoAV
IR8 Element—Direct binding of FXR/RXR heterodimers to the
human apoAV IR8 element was examined. For this purpose,
gel shift assays were performed using in vitro translated hu-
man FXR and RXR and a radiolabeled double-stranded oligo-
nucleotide containing the apoAV IR8 element. The addition of
FXR resulted in the appearance of a weak protein-DNA com-
plex band (Fig. 11, lane 2), a phenomenon that we also per-
ceived in previously published gel shift analysis performed
with other FXREs (Fig. 5B in Ref. 23, Fig. 3B in Ref. 29, and
Fig. 5A in Ref. 30). Nevertheless, this faint band disappeared,
and a robust and more shifted band emerged when both FXR
and RXR were present (Fig. 11, lane 4). This RXR-FXR-IR8
binding was specific, as demonstrated by competition of an
excess of either unlabeled wild-type apoAV IR8 oligonucleotide
(Fig. 11, lanes 5–7) or a cold probe containing the IR1 sequence
of the human I-BABP FXRE (Fig. 11, lanes 17–19). Further-
more, mutation of either half-site (Fig. 10B) abolished the
ability of the probe to compete (Fig. 11, lanes 8–16). These
results demonstrate that FXR-RXR heterodimers are able to
directly and specifically interact with the apoAV IR8 and not
with cryptic binding motifs embedded within this site. We
conclude that this novel IR8 is a bona fide FXR response
element.
ApoAV mRNA Levels Are Not Induced by Treatments with a
FXR Agonist or a Bile Acid—To analyze whether apoAV mRNA
expression is regulated by FXR agonists and bile acids, primary
hepatocytes isolated from cynomolgus liver and human hepa-
toma HepG2 cells were incubated for 48 h in medium contain-
ing GW4064, LCA, or vehicle. Whereas the treatment of hepa-
tocytes with the FXR agonist or LCA increased the expression
of small heterodimer partner and bile salt export pump genes,
no significant induction of apoAV expression was observed
(Fig. 12).
DISCUSSION
The present study aimed to comprehend the mechanisms
controlling the human apoAV gene expression and to identify
factors capable of positively modulating its transcription. Our
data reveal that two nuclear receptors involved in the regula-
tion of triglyceride metabolism, namely PPAR and FXR, may
control the human apoAV gene.
The apoAV gene resides 27 kb distal to apoAIV in the
apoAI/CIII/AIV gene cluster on human chromosome 11q23 (38,
39). Our results showed that the human apoAV gene contains
four exons, with the first intron within the 5-untranslated
regions (Fig. 1A). With the exception of apoAIV (50), both
features are also present in the rest of the apolipoprotein genes
(Fig. 1B). This similarity gives further insight into the under-
standing of the process of evolution of the apolipoprotein genes
from a common ancestor (51). In addition to the previously
reported alternative 3-untranslated regions (39), we found
that the second exon may have alternative length depending on
the use of two distinct acceptor sites. Interestingly, alternative
transcripts have not been reported for other members within
this gene cluster. However, although some variation in terms of
mRNA stability may be inferred, none of the alternative tran-
scripts contains a different coding sequence. Strikingly, we
came across an SNP (A3G) 3 nt upstream from the predicted
translation start codon (Fig. 1C). The incidence of this SNP
(called c.3A3G) and its association with higher triglyceride
levels were recently reported (42). There is another ATG in
frame 9 nt downstream of the start codon (Fig. 1C). The nucle-
otide sequences surrounding both methionine codons conform
to the Kozak consensus sequence (RNNATGG), with a G at 4
and a purine (R), preferably A, 3 nucleotides upstream (52). It
remains as an interesting question for future research to de-
termine whether this c.3A3G polymorphism could modify
the start of translation or reduce the rate of apoAV protein
synthesis. On the other hand, a T3C SNP in the 5-region of
the human apoAV gene, called SNP3, has also been associated
with elevated plasma triglyceride levels (38, 41–45). Luciferase
reporter assays revealed that the change of the common allele
T to C, which is located at position 600 relative to the tran-
scription start site (Fig. 1C), has no significant effect on the
basal activity of the apoAV promoter. Similarly, the induction
by either PPAR or FXR of the apoAV promoter activity was
not affected by this change of T to C (data not shown). Analysis
of the sequence surrounding SNP3 reveals no apparent tran-
scription factor binding sites. In addition, EMSA showed no
binding of nuclear receptors to this region (Fig. 5A and data not
shown). Considered together, these data suggest that this poly-
morphism may not be functional but, as proposed by others
(43), may act as a marker for another functional change else-
where in the gene cluster.
FIG. 11. The FXR-RXR hetero-
dimer binds specifically to the IR8
element of the human apoAV pro-
moter. EMSAs were performed using in
vitro transcribed/translated human FXR
(2.5 l), human RXR (2.5 l), or unpro-
grammed reticulocyte lysate (), when in-
dicated, and a labeled double-stranded ol-
igonucleotide corresponding to nt 109 to
80 (AvIR8) of the human apoAV gene
promoter as described under “Experimen-
tal Procedures.” The lysate volumes were
kept constant by the addition of unpro-
grammed lysate. The competition experi-
ments for binding of FXR-RXR het-
erodimers were performed by adding a
50-, 250-, and 500-fold molar excess of
the indicated unlabeled double-stranded
probes. The mutations present in the
modified versions of wtAvIR8 (mt1AvIR8,
mt2AvIR8, and mt3AvIR8) are shown in
Fig. 10B. The specific FXR-RXR-FXRE
complex is indicated by an arrow. CONT,
FXRE of human I-BABP gene (30); wt,
wild-type; mt, mutated.
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The presence of a TATA box 30 nt upstream of the start of
transcription identified by RLM-RACE along with the results
from reporter experiments showing transcriptional activity
and responsiveness to nuclear receptors validate this proximal
5-flanking region as the promoter of the human apoAV gene.
The expression of apoAI, apoCIII, and apoAIV is controlled by
a common enhancer sequence located at the distal regulatory
region of the apoCIII gene (53). Based on the notion that apoAV
and these apolipoprotein genes evolved from a common ances-
tral gene, it is tempting to speculate that a distal enhancer also
regulates the apoAV gene. If this is the case, however, then the
enhancer for apoAV should be elsewhere within a 26-kb XhoI
fragment that contains only apoAV, which was able to induce
specific expression of human apoAV when injected into mouse
eggs (38). Further work will be required to fully assess this
hypothesis.
Deletion, site-directed mutagenesis, and binding analysis
demonstrated unequivocally that the apoAV gene promoter
responds to bile acids and FXR via a novel response element
(IR8). Furthermore, the IR8 element was capable of conferring
FXRresponsivenessonaheterologouspromoterinacopynumber-
dependent manner, and selective mutation of each half-site in
the IR8 abolished the nuclear receptor response. However,
despite exhaustive efforts, we have not been able to demon-
strate a significant induction of apoAV mRNA levels by either
bile acids or the FXR ligand GW4064 in hepatocytes (Fig. 12).
This paradox suggests that other factors might potentially
interfere in the regulation by FXR. Recent studies are begin-
ning to establish the notion that the DNA sequences of hor-
mone response elements for several nuclear receptors, once
thought to be specific, can be quite varied. The MRP2 ER8, for
example, has been shown to function as a pregnane X receptor
(NR1I2), constitutive androstane receptor (NR1I3), and FXR
response element (23). It is possible that the novel IR8 could
also act as response element for the convergence of alternative
transcription factors present in the systems that we have an-
alyzed, and the response to bile acids depends on the ratio
between FXR and these factors. Alternatively, sequences in the
5-flanking region of human apoAV upstream to position
2455 might respond negatively to bile acids and thereby
counteract the effect through the proximal FXRE. Further
studies will be necessary to determine whether potential acti-
vation of the apoAV gene by bile acids is dependent on a
particular environmental or physiological cue.
The current study shows that treatment of hepatocytes with
a PPAR activator increased apoAV mRNA levels. Consistent
with this observation, induction of apoAV mRNA levels by
fibrates has recently been reported (54). Furthermore, cotrans-
fection of a PPAR expression plasmid induced the activity of
the human apoAV promoter, suggesting that the increase by
PPAR activators occurs, at least in part, via transcriptional
mechanisms. Using 5-deletion, mutagenesis, and gel shift
analysis, a functional PPRE was identified. A reporter con-
struct bearing a mutated version of this PPRE still showed a
minimal transactivation by PPAR. The basis for this residual
response is unclear, and the presence of an additional, weak
response element between nt 617 and 271 should not be
excluded.
It is well established that PPAR activators lower plasma
triglyceride levels by modulating the transcription of several
lipid-related genes (10). PPAR induces the expression of en-
zymes involved in the uptake, transport, and metabolism of
fatty acids. As a result, the substrate availability for triglycer-
ide synthesis and very low density lipoprotein production is
diminished, which will ultimately decrease plasma triglycer-
ide-rich lipoprotein concentrations (11). In addition, activated
PPAR may increase LPL-mediated lipolysis and clearance of
triglyceride-rich lipoprotein particles by stimulating LPL ex-
pression in the liver and by reducing hepatic production of
apoCIII (12–15). Our results demonstrate that apoAV is de
facto a PPAR target gene, which is consistent with the trig-
lyceride-lowering role proposed for apoAV. These findings shed
new light on the mechanisms whereby PPAR agonists lower
plasma triglyceride levels.
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